Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey

C Fotopoulou; M Hall; R Lord; R. Miller; S Sundar; N Roebuck; L Fildes; A Wesselbaum; S. McCormack; J Hickey; J. Ledermann

doi:10.1016/j.clon.2023.10.052

Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey

C Fotopoulou^*, M Hall, R Lord, R. Miller, S Sundar, N Roebuck, L Fildes, A Wesselbaum, S. McCormack, J Hickey, J. Ledermann

^*Corresponding author for this work

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

AIMS: New treatment options for advanced ovarian cancer have the potential to significantly change the treatment pathway in the UK. Understanding the structures and responsibilities of multidisciplinary teams/tumour boards (MDT) and regional variations will enable services to adapt more effectively to these changes.

MATERIALS AND METHODS: The KNOW-OC survey was conducted in 2020 to understand the views of a selected group of 66 healthcare professionals (HCPs) involved in advanced ovarian cancer care in UK hospitals.

RESULTS: The results showed that MDT involvement in the management of advanced ovarian cancer varied depending on pathway stage and line of relapse, with 98.5% of HCPs responding that the MDT was involved in decisions at initial presentation, but only 40.9% for patients with multiple relapses. The MDT was mostly responsible for determining whether the patients would undergo primary or interval cytoreductive surgery according to 75.8% of respondents, and most HCPs (80.3%) stated that tumour dissemination patterns were the most important factor influencing this decision. The most commonly assessed biomarkers at the time of the survey were CA125, gBRCA and tBRCA. Homologous recombination deficiency was viewed as the second most important factor for determining prognosis, but few centres had access to testing at the time of survey completion. The use of active surveillance was expected to decrease in favour of first-line targeted therapies. Nearly all (98.5%) HCPs agreed there is a role for secondary cytoreductive surgery for the treatment of recurrence (for carefully selected patients).

CONCLUSIONS: The results highlighted UK-specific geographical variation in the views of HCPs on MDT involvement and specific practices, such as molecular biomarker testing, and the overall treatment approach. Together, these findings improve the understanding of reported clinical practice across the UK for ovarian cancer and provide insight into decision-making associated with updates to recommendations for best practice (e.g. European Society for Medical Oncology/European Society of Gynaecological Oncology consensus statements) and the introduction of new treatment options.

Original language	English
Journal	Clinical Oncology
DOIs	https://doi.org/10.1016/j.clon.2023.10.052
Publication status	E-pub ahead of print - 29 Oct 2023

Bibliographical note

Acknowledgements:
The authors wish to thank all the healthcare professionals who participated in the survey. OPEN VIE Ltd, doing business as OPEN Health, conducted the data analysis and provided medical writing support (provided by Fiona Glen, PhD and Yusuf Daniju, PhD) for this manuscript, funded by GSK.

Copyright:
© 2023. Published by Elsevier Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clon.2023.10.052

Cite this

Fotopoulou, C., Hall, M., Lord, R., Miller, R., Sundar, S., Roebuck, N., Fildes, L., Wesselbaum, A., McCormack, S., Hickey, J., & Ledermann, J. (2023). Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey. Clinical Oncology. Advance online publication. https://doi.org/10.1016/j.clon.2023.10.052

@article{804cc94ad29742f882284b36a68c018b,

title = "Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey",

abstract = "AIMS: New treatment options for advanced ovarian cancer have the potential to significantly change the treatment pathway in the UK. Understanding the structures and responsibilities of multidisciplinary teams/tumour boards (MDT) and regional variations will enable services to adapt more effectively to these changes.MATERIALS AND METHODS: The KNOW-OC survey was conducted in 2020 to understand the views of a selected group of 66 healthcare professionals (HCPs) involved in advanced ovarian cancer care in UK hospitals.RESULTS: The results showed that MDT involvement in the management of advanced ovarian cancer varied depending on pathway stage and line of relapse, with 98.5% of HCPs responding that the MDT was involved in decisions at initial presentation, but only 40.9% for patients with multiple relapses. The MDT was mostly responsible for determining whether the patients would undergo primary or interval cytoreductive surgery according to 75.8% of respondents, and most HCPs (80.3%) stated that tumour dissemination patterns were the most important factor influencing this decision. The most commonly assessed biomarkers at the time of the survey were CA125, gBRCA and tBRCA. Homologous recombination deficiency was viewed as the second most important factor for determining prognosis, but few centres had access to testing at the time of survey completion. The use of active surveillance was expected to decrease in favour of first-line targeted therapies. Nearly all (98.5%) HCPs agreed there is a role for secondary cytoreductive surgery for the treatment of recurrence (for carefully selected patients).CONCLUSIONS: The results highlighted UK-specific geographical variation in the views of HCPs on MDT involvement and specific practices, such as molecular biomarker testing, and the overall treatment approach. Together, these findings improve the understanding of reported clinical practice across the UK for ovarian cancer and provide insight into decision-making associated with updates to recommendations for best practice (e.g. European Society for Medical Oncology/European Society of Gynaecological Oncology consensus statements) and the introduction of new treatment options.",

author = "C Fotopoulou and M Hall and R Lord and R. Miller and S Sundar and N Roebuck and L Fildes and A Wesselbaum and S. McCormack and J Hickey and J. Ledermann",

note = "Acknowledgements: The authors wish to thank all the healthcare professionals who participated in the survey. OPEN VIE Ltd, doing business as OPEN Health, conducted the data analysis and provided medical writing support (provided by Fiona Glen, PhD and Yusuf Daniju, PhD) for this manuscript, funded by GSK. Copyright: {\textcopyright} 2023. Published by Elsevier Ltd.",

year = "2023",

month = oct,

day = "29",

doi = "10.1016/j.clon.2023.10.052",

language = "English",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier",

}

TY - JOUR

T1 - Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK

T2 - Results From the KNOW-OC Survey

AU - Fotopoulou, C

AU - Hall, M

AU - Lord, R

AU - Miller, R.

AU - Sundar, S

AU - Roebuck, N

AU - Fildes, L

AU - Wesselbaum, A

AU - McCormack, S.

AU - Hickey, J

AU - Ledermann, J.

N1 - Acknowledgements: The authors wish to thank all the healthcare professionals who participated in the survey. OPEN VIE Ltd, doing business as OPEN Health, conducted the data analysis and provided medical writing support (provided by Fiona Glen, PhD and Yusuf Daniju, PhD) for this manuscript, funded by GSK. Copyright: © 2023. Published by Elsevier Ltd.

PY - 2023/10/29

Y1 - 2023/10/29

N2 - AIMS: New treatment options for advanced ovarian cancer have the potential to significantly change the treatment pathway in the UK. Understanding the structures and responsibilities of multidisciplinary teams/tumour boards (MDT) and regional variations will enable services to adapt more effectively to these changes.MATERIALS AND METHODS: The KNOW-OC survey was conducted in 2020 to understand the views of a selected group of 66 healthcare professionals (HCPs) involved in advanced ovarian cancer care in UK hospitals.RESULTS: The results showed that MDT involvement in the management of advanced ovarian cancer varied depending on pathway stage and line of relapse, with 98.5% of HCPs responding that the MDT was involved in decisions at initial presentation, but only 40.9% for patients with multiple relapses. The MDT was mostly responsible for determining whether the patients would undergo primary or interval cytoreductive surgery according to 75.8% of respondents, and most HCPs (80.3%) stated that tumour dissemination patterns were the most important factor influencing this decision. The most commonly assessed biomarkers at the time of the survey were CA125, gBRCA and tBRCA. Homologous recombination deficiency was viewed as the second most important factor for determining prognosis, but few centres had access to testing at the time of survey completion. The use of active surveillance was expected to decrease in favour of first-line targeted therapies. Nearly all (98.5%) HCPs agreed there is a role for secondary cytoreductive surgery for the treatment of recurrence (for carefully selected patients).CONCLUSIONS: The results highlighted UK-specific geographical variation in the views of HCPs on MDT involvement and specific practices, such as molecular biomarker testing, and the overall treatment approach. Together, these findings improve the understanding of reported clinical practice across the UK for ovarian cancer and provide insight into decision-making associated with updates to recommendations for best practice (e.g. European Society for Medical Oncology/European Society of Gynaecological Oncology consensus statements) and the introduction of new treatment options.

AB - AIMS: New treatment options for advanced ovarian cancer have the potential to significantly change the treatment pathway in the UK. Understanding the structures and responsibilities of multidisciplinary teams/tumour boards (MDT) and regional variations will enable services to adapt more effectively to these changes.MATERIALS AND METHODS: The KNOW-OC survey was conducted in 2020 to understand the views of a selected group of 66 healthcare professionals (HCPs) involved in advanced ovarian cancer care in UK hospitals.RESULTS: The results showed that MDT involvement in the management of advanced ovarian cancer varied depending on pathway stage and line of relapse, with 98.5% of HCPs responding that the MDT was involved in decisions at initial presentation, but only 40.9% for patients with multiple relapses. The MDT was mostly responsible for determining whether the patients would undergo primary or interval cytoreductive surgery according to 75.8% of respondents, and most HCPs (80.3%) stated that tumour dissemination patterns were the most important factor influencing this decision. The most commonly assessed biomarkers at the time of the survey were CA125, gBRCA and tBRCA. Homologous recombination deficiency was viewed as the second most important factor for determining prognosis, but few centres had access to testing at the time of survey completion. The use of active surveillance was expected to decrease in favour of first-line targeted therapies. Nearly all (98.5%) HCPs agreed there is a role for secondary cytoreductive surgery for the treatment of recurrence (for carefully selected patients).CONCLUSIONS: The results highlighted UK-specific geographical variation in the views of HCPs on MDT involvement and specific practices, such as molecular biomarker testing, and the overall treatment approach. Together, these findings improve the understanding of reported clinical practice across the UK for ovarian cancer and provide insight into decision-making associated with updates to recommendations for best practice (e.g. European Society for Medical Oncology/European Society of Gynaecological Oncology consensus statements) and the introduction of new treatment options.

U2 - 10.1016/j.clon.2023.10.052

DO - 10.1016/j.clon.2023.10.052

M3 - Article

C2 - 37923688

SN - 0936-6555

JO - Clinical Oncology

JF - Clinical Oncology

ER -

Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this